EP0193602A1 - Triglyzeridpräparate zur verhütung von katabolismus - Google Patents

Triglyzeridpräparate zur verhütung von katabolismus

Info

Publication number
EP0193602A1
EP0193602A1 EP19850904733 EP85904733A EP0193602A1 EP 0193602 A1 EP0193602 A1 EP 0193602A1 EP 19850904733 EP19850904733 EP 19850904733 EP 85904733 A EP85904733 A EP 85904733A EP 0193602 A1 EP0193602 A1 EP 0193602A1
Authority
EP
European Patent Office
Prior art keywords
oil
acid
structured lipid
chain triglyceride
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19850904733
Other languages
English (en)
French (fr)
Inventor
Vigen K. Babayan
George L. Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTER FOR NUTRITIONAL RESEARCH CHARITABLE TRUST
Original Assignee
CENTER FOR NUTRITIONAL RESEARCH CHARITABLE TRUST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTER FOR NUTRITIONAL RESEARCH CHARITABLE TRUST filed Critical CENTER FOR NUTRITIONAL RESEARCH CHARITABLE TRUST
Publication of EP0193602A1 publication Critical patent/EP0193602A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Definitions

  • This invention relates to triglyceride preparations for enteral or parentral administration to prevent catabolism and to increase protein synthesis in subjects undergoing severe metabolic stress.
  • This invention provides medium chain and long chain fatty acids chemically synthesized into structured triglycerides (lipids) for enteral or parentral administration as the lipid calorie source, in subjects undergoing severe metabolic stress.
  • lipids structured triglycerides
  • the structural lipids of this invention are randomly rearranged mixtures of medium chain triglycerides (MCT) and long chain triglycerides (LCT). They may be represented by the following formula,
  • R 1 and R 2 may be independently a C 6 to C 12 acid, or a C 12 to C 18 ' acid, and R 3 may be a C 18 " or C 18 " acid.
  • R 1 may be a C 6 to C 12 acid
  • R 2 a C 12 to C 18 acid.
  • C 18 ', C 18 " and C 18 " represent the number of double bonds in the fatty acid moiety being one, two and three double bonds respectively.
  • the medium chain triglycerides may be lauric oils such as, balassee oil, coconut oil, cohune oil, palm kernel oil, tucum oil and fractions thereof.
  • the preferred medium chain triglyceride oil is coconut oil.
  • the long chain triglycerides may be polyunsaturated vegetable oils such as, corn oil, peanut oil, safflower oil, soybean oil, sunflower seed oil, and fish oils.
  • the preferred long chain triglyceride oils are safflower oil, soybean oil, and sunflower seed oil.
  • the percent composition of mixtures of medium chain triglycerides to long chain triglycerides of this invention may be 70 to 30%, 80 to 20%, 85 to 15%, or 90 to 10%. The 80 to 20% and the 85 to 15% mixtures are most preferred.
  • the structured lipids of this invention may be mixtures of coconut oil and soybean oil, which lipids may have the following fatty acid carbon chain length (CCL) composition.
  • CCL fatty acid carbon chain length
  • the present invention provides enteral and parenteral preparations for use in stressed patients to prevent catabolism and to increase protein synthesis.
  • the preparations provide from about 15 to 85% of the fat calories required in the stressed patient.
  • compositions of this invention provide in a 70 Kg man, from about 0.7 gms of fat/Kg of body weight day to about 4.0 gms of fat/Kg of body weight/day.
  • the lipid compositions are preferably administered with additional amino acids, vitamins and minerals as required. Modified amino acid formulas specifically designed for stressed subjects are preferred.
  • the amino acids, vitamins and minerals can be administered in the same solution as the structured lipids or separately. It is preferred that the component groups be separately packaged to facilitate tailoring the diet to the patients specific needs.
  • formulations may include preservatives or stablizers, as required.
  • a structural lipid preparation of this invention is compared with a medium chain lipid, and a long chain lipid for the oxidation of lipids in traumatized animals.
  • Group I a 20% medium chain lipid emulsion composed of 72.5% capric acid (C 8:0) and 27.5% coprylic acid (C 10:0) (obtained from Travenol Laboratories, Inc; Deerfield/ Illinois).
  • Group II a 20% long chain triglyceride emulsion (20% Travamulsion®, Travenol Laboratories)
  • Group III a 20% lipid emulsion composed of structured triglycerides chemically synthesized from 80% coconut oil and 20% soybean oil.
  • Captex 710A Lot No. KH4022A Capital City Products Co., Columbus, Ohio
  • the rats were placed in metabolic chambers that permitted the collection and analysis of their expired breath. At 15 minute intervals for twelve hours, the specific activity of expired carbon dioxide was determined. At the end of the study, the animals were sacrificed
  • Such structured lipids should be preferable and suitable for both enteral and parenteral nutrition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19850904733 1984-09-13 1985-09-13 Triglyzeridpräparate zur verhütung von katabolismus Withdrawn EP0193602A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65077184A 1984-09-13 1984-09-13
US650771 1984-09-13

Publications (1)

Publication Number Publication Date
EP0193602A1 true EP0193602A1 (de) 1986-09-10

Family

ID=24610217

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850904733 Withdrawn EP0193602A1 (de) 1984-09-13 1985-09-13 Triglyzeridpräparate zur verhütung von katabolismus

Country Status (2)

Country Link
EP (1) EP0193602A1 (de)
WO (1) WO1986001715A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227403A (en) * 1986-10-01 1993-07-13 The Nisshin Oil Mills, Ltd. Fats and oils having superior digestibility and absorptivity
JPH0832628B2 (ja) * 1986-12-17 1996-03-29 株式会社ミドリ十字 トリグリセリド組成物
US4810726A (en) * 1987-04-01 1989-03-07 New England Deaconess Hospital Corporation Kernel oils and disease treatment
FR2618332B1 (fr) * 1987-07-23 1990-04-27 Synthelabo Emulsion lipidique destinee a la nutrition parenterale ou enterale
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
FR2877577A1 (fr) * 2004-11-09 2006-05-12 Jean Pierre Maloisel Extraits de fruits d'astrocaryum aculeatum a visee anti hypertrophie benigne de la prostate, anti inflammatoire et anti oxydante
AU2006330112A1 (en) * 2005-12-24 2007-07-05 Dsm Ip Assets B.V. Long term weight maintenance
WO2011115184A1 (ja) * 2010-03-18 2011-09-22 日清オイリオグループ株式会社 生体内の蛋白質の分解抑制剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268340A (en) * 1965-08-30 1966-08-23 Drew Chem Corp Margarine oil and margarine made therefrom
US4329359A (en) * 1979-12-28 1982-05-11 University Of Kentucky Research Foundation Method for improving the metabolic stability and survival of newborn pigs
US4282265A (en) * 1980-01-14 1981-08-04 Bristol-Myers Company Fat compositions for infant formulas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8601715A1 *

Also Published As

Publication number Publication date
WO1986001715A1 (en) 1986-03-27

Similar Documents

Publication Publication Date Title
US4847296A (en) Triglyceride preparations for the prevention of catabolism
Traul et al. Review of the toxicologic properties of medium-chain triglycerides
EP1039892B1 (de) Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
US5700837A (en) Method and composition for normalizing injury response
US6080787A (en) Methods for reducing the incidence of necrotizing enterocolitis
EP0440341B1 (de) Zusammensetzungen essentieller Fettsäuren und Therapie
EP0567216A1 (de) Zusammensetzung aus Omega-3 Fettsäuren enthaltendem Material und einem Glutathionstimulator zur Behandlung von Immunkrankheiten und viralen Infektionen
JPS62129389A (ja) 経腸製品および非経口製品に好適な栄養脂肪
DE69016200T2 (de) Kurzkettige triglyceride.
CA1132907A (en) Acyl-carnitines and use thereof in parenteral administration of triglycerides
EP0638061B1 (de) Einfach ungesättigte fette als nahrungszusätze zur minimierung der folgen katabolischer erkrankungen
EP0451750B1 (de) Verwendung von kurzkettige Fettsäuren enthaltenden Lipiden zur Aufrechterhaltung der Integrität und der Funktion des Magen-Darm-Kanals
US5922345A (en) Nutrition
EP0490561B1 (de) Nahrung
JPH06511384A (ja) ヒトおよび動物用の栄養剤
EP0193602A1 (de) Triglyzeridpräparate zur verhütung von katabolismus
AU1177595A (en) Butyric ester cyto-differentiating agents
JPH0347119A (ja) γ―リノレン酸含有栄養組成物
CA1242974A (en) Parenteral nutrition with medium and long chain triglycerides
JPH10500937A (ja) セサミン系リグナンの抗炎症及び感染防護効果
JP4394174B2 (ja) 炎症性腸疾患治療剤
JP4139544B2 (ja) 血糖値低下剤
US4330557A (en) Acyl-carnitine and use thereof in parenteral administration of triglycerides
JP6470879B1 (ja) 抗炎症剤、抗炎症用医薬組成物、抗炎症用食品組成物
JP3947322B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860814

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BLACKBURN, GEORGE, L.

Inventor name: BABAYAN, VIGEN, K.